

Highlights of This Issue 1707

SPECIAL FEATURES

Special Report

- 1709** AACR Celebrates 50 Years of Tobacco Research and Policy
Roy S. Herbst, Jennifer A. Hobin, and Ellen R. Gritz;
Writing Committee for the AACR Subcommittee on Tobacco and Cancer

Special Commentary

- 1719** It Shouldn't Take Another 50 Years: Accelerating Momentum to End the Tobacco Epidemic
Howard K. Koh

CCR Translations

- 1721** Seeing the Forest for the Trees: Kidney Oncogenomes in Relation to Therapeutic Outcomes
David D. Chism and W. Kimryn Rathmell
See related article, p. 1955
- 1724** Estrogen Receptor Mutations in Breast Cancer—New Focus on an Old Target
Corrinne V. Segal and Mitch Dowsett
See related article, p. 1757
- 1727** Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?
Paul A. Bunn Jr, Fred R. Hirsch, and Dara L. Aisner
See related article, p. 1946

Statistics in Clinical Cancer Research

- 1730** Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
Cong Chen and Robert A. Beckman


CCR Drug Updates

- 1735** Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
Varsha Gandhi, William Plunkett, and Jorge E. Cortes

Molecular Pathways

- 1741** Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer
Silvana Paredes, Lidia Villanova, and Katrin F. Chua

Review

- 1747** Intratumoral Immunization: A New Paradigm for Cancer Therapy
 Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, and Ronald Levy

HUMAN CANCER BIOLOGY



- 1757** Emergence of Constitutively Active Estrogen Receptor- α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
 Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer Giltane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, and Vincent A. Miller
See related article, p. 1724
- 1768** T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
 Rikke Lyngaa, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thruue, Dafina Ibrani, Özcan Met, Per thor Straten, Paul Nghiem, Jürgen C. Becker, and Sine Reker Hadrup
- 1779** Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma
Dong Ni, Xin Ma, Hong-Zhao Li, Yu Gao, Xin-Tao Li, Yu Zhang, Qing Ai, Peng Zhang, Er-Lin Song, Qing-Bo Huang, Yang Fan, and Xu Zhang

Table of Contents

- 1791** **Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer**
Tobias Lange, Mareike Kupfernagel, Daniel Wicklein, Florian Gebauer, Hanna Maar, Kathrin Brügge, Imke Müller, Ronald Simon, Thorsten Schlomm, Guido Sauter, and Udo Schumacher

- 1803** **Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting *PIK3CD* and Predicts the Prognosis of Human Glioblastoma**



Yu Shi, Cong Chen, Xia Zhang, Qing Liu, Jin-Ling Xu, Hua-Rong Zhang, Xiao-Hong Yao, Tao Jiang, Zhi-Cheng He, Yong Ren, Wei Cui, Chuan Xu, Ling Liu, You-Hong Cui, Shi-Zhu Yu, Yi-Fang Ping, and Xiu-Wu Bian

CANCER THERAPY: PRECLINICAL

- 1814** **Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma**



Naoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, Kentaro Yamanaka, Aya Kita, Masamichi Mori, Sosuke Miyoshi, and Sadao Kuromitsu

- 1823** **A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor-Infiltrating Lymphocytes**

Nathalie Demotte, René Bigirimana, Grégoire Wierers, Vincent Stroobant, Jean-Luc Squifflet, Javier Carrasco, Kris Thielemans, Jean-François Baurain, Patrick Van Der Smissen, Pierre J. Courttoy, and Pierre van der Bruggen

- 1834** **Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers**



Pablo D. Garcia, John L. Langowski, Yingyun Wang, Min Chen, Joseph Castillo, Christie Fanton, Marjorie Ison, Tatiana Zavorotinskaya, Yumin Dai, Jing Lu, Xiao-Hong Niu, Stephen Basham, Julie Chan, Jianjun Yu, Michael Doyle, Paul Feucht, Robert Warne, Jamie Narberes, Tiffany Tsang, Christine Fritsch, Audrey Kauffmann, Estelle Pfister, Peter Drucekes, Joerg Trappe, Christopher Wilson, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Mika Lindvall, Cornelia Bellamacina, J. Alex Aycinena, Richard Zang, Jocelyn Holash, and Matthew T. Burger

- 1846** **Cross-talk between EphA2 and Braf/CRaf Is a Key Determinant of Response to Dasatinib**
Jie Huang, Wei Hu, Justin Bottsford-Miller, Tao Liu, Hee Dong Han, Behrouz Zand, Sunila Pradeep, Ju-Won Roh, Duangmani Thanappapasr, Heather J. Dalton, Chad V. Pecot, Rajesh Rupaimoole, Chunhua Lu, Bryan Fellman, Diana Urbauer, Yu Kang, Nicholas B. Jennings, Li Huang, Michael T. Deavers, Russell Broaddus, Robert L. Coleman, and Anil K. Sood

IMAGING, DIAGNOSIS, PROGNOSIS

- 1856** **Functional Identification of Cancer-Specific Methylation of *CD01*, *HOXA9*, and *TAC1* for the Diagnosis of Lung Cancer**

John Wrangle, Emi Ota Machida, Ludmila Danilova, Alicia Hulbert, Noreli Franco, Wei Zhang, Sabine C. Glöckner, Mathewos Tessema, Leander Van Neste, Hariharan Easwaran, Kornel E. Schuebel, Julien Licchesi, Craig M. Hooker, Nita Ahuja, Jun Amano, Steven A. Belinsky, Stephen B. Baylin, James G. Herman, and Malcolm V. Brock

- 1865** **Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis**
Haeryoung Kim, Burcu Saka, Spencer Knight, Michael Borges, Erica Childs, Alison Klein, Christopher Wolfgang, Joseph Herman, Volkan N. Adsay, Ralph H. Hruban, and Michael Goggins

- 1873** **Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma**

Markus Riestler, Lillian Werner, Joaquim Bellmunt, Shamini Selvarajah, Elizabeth A. Guancial, Barbara A. Weir, Edward C. Stack, Rachel S. Park, Robert O'Brien, Fabio A.B. Schutz, Toni K. Choueiri, Sabina Signoretti, Josep Lloreta, Luigi Marchionni, Enrique Gallardo, Federico Rojo, Denise I. Garcia, Yvonne Chekaluk, David J. Kwiatkowski, Bernard H. Bochner, William C. Hahn, Azra H. Ligon, Justine A. Barletta, Massimo Loda, David M. Berman, Philip W. Kantoff, Franziska Michor, and Jonathan E. Rosenberg



Table of Contents

1884 **Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma**

Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszczkowski, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, and Andrew X. Zhu

1891 **Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer**

Maria-Gabriela Anitei, Guy Zeitoun, Bernhard Mlecnik, Florence Marliot, Nacilla Haicheur, Ana-Maria Todosi, Amos Kirilovsky, Christine Lagorce, Gabriela Bindea, Dan Ferariu, Mihai Danciu, Patrick Bruneval, Viorel Scripcariu, Jean-Marc Chevallier, Franck Zinzindohoué, Anne Berger, Jérôme Galon, and Franck Pagès

CANCER THERAPY: CLINICAL

1900 **A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothed Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors**

Jordi Rodon, Hussein A. Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, Jose Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine L. Rose, Dereck D. Amakye, Reinhard Dummer, and Alain C. Mita

1910 **Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial**



Susan R. Mallery, Meng Tong, Brian S. Shumway, Alice E. Curran, Peter E. Larsen, Gregory M. Ness, Kelly S. Kennedy, George H. Blakey, George M. Kushner, Aaron M. Vickers, Brian Han, Ping Pei, and Gary D. Stoner

1925 **Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer**

Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillissen, Gary R. Hudes, Tao Wang, Judith Scranton, and Michael N. Pollak

1935 **Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy**

Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhuo Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, Joseph T. Beck, Emmanuelle Di Tomaso, David W. Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, and Jose Baselga

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

1946 **Prediction of Survival in Resected Non-Small Cell Lung Cancer Using a Protein Expression-Based Risk Model: Implications for Personalized Chemoprevention and Therapy**



Kathryn A. Gold, Edward S. Kim, Diane D. Liu, Ping Yuan, Carmen Behrens, Luisa M. Solis, Humam Kadara, David C. Rice, Ignacio I. Wistuba, Stephen G. Swisher, Wayne L. Hofstetter, J. Jack Lee, and Waun K. Hong
See related article, p. 1727

1955 **Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy**



Martin H. Voss, A. Ari Hakimi, Can G. Pham, A. Rose Brannon, Ying-Bei Chen, Luis F. Cunha, Oguz Akin, Han Liu, Shugaku Takeda, Sasinya N. Scott, Nicholas D. Succi, Agnes Viale, Nikolaus Schultz, Chris Sander, Victor E. Reuter, Paul Russo, Emily H. Cheng, Robert J. Motzer, Michael F. Berger, and James J. Hsieh
See related article, p. 1721

1965 **BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact**




Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzannah C. Boyd, Julie Howle, Robyn Saw, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, and Georgina V. Long

Table of Contents

- 1978** A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Sheng-Fang Su, André Luís de Castro Abreu, Yoshitomo Chihara, Yvonne Tsai, Claudia Andreu-Vieyra, Siamak Daneshmand, Eila C. Skinner, Peter A. Jones, Kimberly D. Siegmund, and Gangning Liang
- 1990** Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11
Ross M. Drayton, Ewa Dudzic, Stefan Peter, Simone Bertz, Arndt Hartmann, Helen E. Bryant, and James WF. Catto
- 2001** The Impact of *EGFR* T790M Mutations and *BIM* mRNA Expression on Outcome in Patients with *EGFR*-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez-Capitán, Jordi Bertran-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massuti, Jia Wei, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario Garcia-Campelo, Santiago Viteri, Miquel Taron, Mayumi Ono, Petros Giannikopoulos, Trever Bivona, and Rafael Rosell

LETTERS TO THE EDITOR

- 2011** Definition of Primary and Secondary Glioblastoma—Letter
 Peter Werner, Dominik Fritzsche, Heidrun Holland, Manfred Bauer, Wolfgang Krupp, Karl-Titus Hoffmann, Dorothee Saur, Florian Then Bergh, Osama Sabri, and Henryk Barthel
- 2013** Definition of Primary and Secondary Glioblastoma—Response
Hiroko Ohgaki, Peter Burger, and Paul Kleihues
- 2014** Novel Clinically Relevant Genes in GIST—Letter
M.A. Pantaleo, M. Nannini, A. Astolfi, and G. Biasco
- 2015** Novel Clinically Relevant Genes in GIST—Response
Peter Birner and Berthold Streubel


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a lymph node metastasis from a patient with prostate cancer. Lectin histochemistry with *Helix pomatia* agglutinin shows a decreasing surface presentation of terminal GalNAc- and GlcNAc-residues in lymph node metastasis. In conjunction with this finding, the authors demonstrate that metastatic prostate cancer cells can extravasate in the absence of selectins. For details, see the article by Lange and colleagues on page 1791 of this issue.



Clinical Cancer Research

20 (7)

Clin Cancer Res 2014;20:1707-2015.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.